Gregory S Gorman

Summary

Affiliation: Southern Research Institute
Country: USA

Publications

  1. ncbi In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid
    Gregory S Gorman
    Southern Research Institute, Birmingham, Alabama 35205, USA
    Drug Metab Dispos 35:1157-64. 2007
  2. ncbi In-vitro and in-vivo metabolic studies of the candidate chemopreventative pentamethylchromanol using liquid chromatography/tandem mass spectrometry
    Gregory S Gorman
    Toxicology and Bioanalytical Science Department, Southern Research Institute, Birmingham, AL 35205, USA
    J Pharm Pharmacol 61:1309-18. 2009
  3. ncbi Interspecies pharmacokinetics and in vitro metabolism of SQ109
    Lee Jia
    Developmental Therapeutics Program, National Cancer Institute, NIH, 6130 Executive Blvd, Rm 8042, Rockville, MD 20852, USA
    Br J Pharmacol 147:476-85. 2006
  4. ncbi Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate
    Lee Jia
    National Cancer Institute, Rm 8042, 6130 Executive Blvd, Rockville, MD 20852, USA
    Cancer Chemother Pharmacol 61:63-73. 2008
  5. ncbi Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization
    Lee Jia
    Developmental Therapeutics Program, National Cancer Institute NIH, Executive Plaza North Rm 8042, 6130 Executive Blvd, Rockville, MD 20852, USA
    J Pharm Biomed Anal 37:793-9. 2005

Collaborators

Detail Information

Publications5

  1. ncbi In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid
    Gregory S Gorman
    Southern Research Institute, Birmingham, Alabama 35205, USA
    Drug Metab Dispos 35:1157-64. 2007
    ..Kinetic analysis of eight of the detected metabolites indicated that four seemed to follow classical hyperbolic kinetics, whereas the remaining four showed evidence of either autoactivation or substrate inhibition...
  2. ncbi In-vitro and in-vivo metabolic studies of the candidate chemopreventative pentamethylchromanol using liquid chromatography/tandem mass spectrometry
    Gregory S Gorman
    Toxicology and Bioanalytical Science Department, Southern Research Institute, Birmingham, AL 35205, USA
    J Pharm Pharmacol 61:1309-18. 2009
    ..Additional investigations compare in-vitro data with in-vivo metabolic data from rats and dogs...
  3. ncbi Interspecies pharmacokinetics and in vitro metabolism of SQ109
    Lee Jia
    Developmental Therapeutics Program, National Cancer Institute, NIH, 6130 Executive Blvd, Rm 8042, Rockville, MD 20852, USA
    Br J Pharmacol 147:476-85. 2006
    ..P450 reaction phenotyping using recombinant cDNA-expressed human CYPs in conjunction with specific CYP inhibitors indicated that CYP2D6 and CYP2C19 were the predominant CYPs involved in SQ109 metabolism...
  4. ncbi Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate
    Lee Jia
    National Cancer Institute, Rm 8042, 6130 Executive Blvd, Rockville, MD 20852, USA
    Cancer Chemother Pharmacol 61:63-73. 2008
    ..To characterize the stability, pharmacokinetics and metabolism of analogs of gossypol, apogossypol and apogossypol hexaacetate to provide a basis for comparison...
  5. ncbi Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization
    Lee Jia
    Developmental Therapeutics Program, National Cancer Institute NIH, Executive Plaza North Rm 8042, 6130 Executive Blvd, Rockville, MD 20852, USA
    J Pharm Biomed Anal 37:793-9. 2005
    ..The elimination t(1/2) ranged from 4.4 to 21.1h dependent on the routes. The oral bioavailability was 5.1 (SQ59), 20.1 (SQ37) and 7.8% (SQ109), respectively. Both SQ37 and SQ109 possess good pharmacokinetic properties...